ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Leukemia
Acute Myeloid Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Toronto, ON, CAN:

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)
Drug: gilteritinib

Phase 3

Astellas
Astellas

Toronto, Ontario, Canada and 125 other locations

Locations recently updated

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Toronto, Ontario, Canada and 164 other locations

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...

Active, not recruiting
AML
Acute Myelogenous Leukemia
Drug: Iomab-B
Drug: Conventional Care

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Toronto, Ontario, Canada and 23 other locations

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (STIMULUS-AML1)

This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 i...

Active, not recruiting
Acute Myeloid Leukemia
Drug: MBG453
Drug: Venetoclax

Phase 2

Novartis
Novartis

Toronto, Ontario, Canada and 27 other locations

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Quizartinib
Drug: Cytarabine

Phase 1, Phase 2

Daiichi Sankyo
Daiichi Sankyo

Toronto, Ontario, Canada and 27 other locations

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...

Enrolling
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Fludarabine

Phase 3

LLS PedAL Initiative, LLC

Toronto, Ontario, Canada and 73 other locations

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. ...

Active, not recruiting
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Acute Myeloid Leukemia (AML)
Drug: azacitidine
Drug: gilteritinib

Phase 3

Astellas
Astellas

Toronto, Ontario, Canada and 110 other locations

A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Toronto, Ontario, Canada and 160 other locations

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitr...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: AG-120

Phase 1, Phase 2

Celgene
Celgene

Toronto, Ontario, Canada and 48 other locations

Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

dose of BMS-986497 in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic sy...

Enrolling
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Drug: BMS-986497

Phase 1

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Toronto, Ontario, Canada and 10 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems